+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07778446

Phase 12 Study Evaluating Intravenous CRT-402 CAR-T Cell Therapy for Refractory Autoimmune Diseases

Led by Myeloid Therapeutics · Updated on 2026-10-22

34

Participants Needed

1

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying CRT-402, an in vivo CD19-targeted CAR-T cell therapy, in people with active refractory autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies. This Phase 12, open-label, dose escalation and expansion trial aims to evaluate the safety, tolerability, preliminary effectiveness, and how the body processes CRT-402. The study focuses on patients who have not responded adequately to standard treatments. Participants will receive CRT-402 through an intravenous infusion. The dose will be increased carefully according to safety criteria to identify the recommended dose for further study. This trial is the first to test CRT-402 in humans and will monitor multiple dose levels. Treatment and follow-up will continue according to the study schedule to assess effects and side effects. During the trial, participants will attend study visits for assessments including safety monitoring for adverse events and immune reactions up to 52 weeks. Researchers will also collect blood samples to study pharmacokinetics and immune responses. The main outcomes measured are the incidence and severity of treatment-related adverse events, including specific immune syndromes. The total duration of participation includes treatment and follow-up periods to gather comprehensive data on CRT-402s effects.

CONDITIONS

Brief Title

A Study to Test CRT-402 in Refractory Autoimmune Disease

Research Team

C

Clinical Department

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here